Improved method for synthesis of low molecular weight protamine–siRNA conjugate (2018)
Sequence: VSRRRRRRGGRRRR
| Experiment Id | EXP002033 |
|---|---|
| Paper | Improved method for synthesis of low molecular weight protamine–siRNA conjugate |
| Peptide | LMWP |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Equivalent to siRNA dose (1:1 monomeric conjugate) |
| Rna Concentration | Typically 50–100 nM (cell studies) |
| Mixing Ratio | 1:1 (covalent conjugate) |
| Formulation Format | CPP–siRNA covalent conjugate |
| Formulation Components | LMWP + PEG linker (NHS–PEG–OPSS or NHS–PEG–MAL) + siRNA |
| Size Nm | 2.50 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HCT116 colon cancer cells; MDA-MB-231-EGFP cells |
| Animal Model | |
| Administration Route | |
| Output Type | cellular uptake and gene silencing |
| Output Value | EGFP expression reduced to ~21% of control |
| Output Units | |
| Output Notes | Confocal microscopy shows cytosolic localization; FACS confirms potent RNAi vs naked siRNA or complexes |
| Toxicity Notes | No significant cytotoxicity reported |
| Curation Notes |